Quantitative Vibration Perception Threshold in Assessing Diabetic Polyneuropathy: Should the Cut-off Value Be Adjusted for Chinese Individuals with Type 2 Diabetes?
Overview
Affiliations
Aims/introduction: To examine the performance and identify the optimal threshold of vibration perception threshold (VPT) for diagnosing diabetic polyneuropathy (DPN) in a Chinese population according to multiple definitions of DPN as gold standards.
Materials And Methods: VPT was determined in 421 Chinese individuals with type 2 diabetes, who simultaneously completed a questionnaire of neuropathic symptoms, and underwent the assessment of signs of peripheral neuropathy and electromyography tests. Three definitions of DPN (i.e., clinician-diagnosed DPN, abnormal nerve conduction and confirmed DPN) were taken as reference gold standards.
Results: Vibration perception threshold was a specific measure for all three groups of DPN outcomes, with the highest specificity noted for clinician-diagnosed DPN (85.1%). The specificity for abnormal nerve conduction and confirmed DPN was 77.0 and 76.6%, respectively. The sensitivity of VPT was 67.0% for clinician-diagnosed DPN, 66.5% for abnormal nerve conduction and 67.2% for confirmed DPN. The optimal cut-off threshold for abnormal nerve conduction, as well as confirmed DPN, was VPT >14.9 V. The specificity and sensitivity of VPT >14.9 V as the cut-off value for clinician-diagnosed DPN were 85.6 and 66.2%, respectively. When taking clinician-diagnosed DPN as the gold standard, the performance of VPT for diagnosing DPN was best with an area under the curve value of 0.804.
Conclusions: VPT measured using the neurothesiometer had relatively high specificity and best performance for diagnosing DPN when clinician-diagnosed DPN rather than abnormal nerve conduction was taken as the gold standard in a Chinese population. A VPT value of ≥15 V might be equally applicable for diagnosing DPN in a Chinese population.
Liu S, Ding H, Li D, Lu F, Luo G, He Y Int J Nurs Stud Adv. 2025; 8:100291.
PMID: 39896918 PMC: 11787437. DOI: 10.1016/j.ijnsa.2025.100291.
Causality between sarcopenia and diabetic neuropathy.
Fang Y, Yuan X, Zhang Q, Liu J, Yao Q, Ye X Front Endocrinol (Lausanne). 2024; 15:1428835.
PMID: 39345878 PMC: 11427279. DOI: 10.3389/fendo.2024.1428835.
Zhang Y, Zheng B, Li Y, Shen X, Huang L, Zhao F Front Endocrinol (Lausanne). 2024; 15:1357294.
PMID: 38872969 PMC: 11169863. DOI: 10.3389/fendo.2024.1357294.
Chattopadhyay S, Goswami S, Sengupta N, Baidya A BMJ Open. 2024; 14(6):e082193.
PMID: 38862223 PMC: 11168183. DOI: 10.1136/bmjopen-2023-082193.
Early detection of diabetic neuropathy based on health belief model: a scoping review.
Purwanti O, Nursalam N, Pandin M Front Endocrinol (Lausanne). 2024; 15:1369699.
PMID: 38721145 PMC: 11076868. DOI: 10.3389/fendo.2024.1369699.